

Table 1

ARIMA models for chronic high dose recipients who experienced a decrease of at least 50% OME/day. The second column (pdq) indicates best parameters for model fit, p-value determines significance and intervention estimate indicates a decrease (if negative) or and increase trend (if positive).

Chronic high dose recipients ($\geq 50\%$ dose reduction)				
Intervention tested	ARIMA best Fit (pdq)	p-value	Intervention estimate (95% CI)	Interpretation
Step – CDC guideline	(2,1,3)	0.834	0.0006 (-0.0053, 0.0066)	Intervention not significant
Step – Canadian prescribing guidelines	(2,1,3)	0.765	-0.0009 (-0.0070, 0.0051)	Intervention not significant
Step – SOP guidelines	(2,1,3)	0.040	-0.0063 (-0.0124, -0.0003)	Intervention is significant; effect estimate indicates lower incidence of potential tapering
Step – CPSA's Snapshot Report	(3,0,1)	<0.001	-0.0021 (-0.0029, -0.0014)	Intervention is significant; effect estimate indicates lower incidence of potential tapering
Ramp – CDC guideline	(1,0,1)	0.032	-0.0001 (-0.0002, -1e-05)	Intervention is significant; effect estimate indicates lower incidence of potential tapering
Ramp – Canadian prescribing guidelines	(3,0,1)	0.005	-0.0002 (-0.0003, -5e-05)	Intervention is significant; effect estimate indicates lower incidence of potential tapering
Ramp – SOP guidelines	(3,0,1)	0.005	-0.0002 (-0.0003, -5e-05)	Intervention is significant; effect estimate indicates lower incidence of potential tapering
Ramp – 1st CPSA's Snapshot Report	(1,0,1)	0.011	-0.0001 (-0.0002, -3e-05)	Intervention is significant; effect estimate indicates lower incidence of potential tapering

Table 2

ARIMA models for chronic very high dose recipients who experienced a decrease of at least 50% OME/day. The second column (pdq) indicates best parameters for model fit, p-value determines significance and intervention estimate indicates a decrease (if negative) or an increase trend (if positive).

Chronic very high dose recipients ($\geq 50\%$ dose reduction)				
Intervention tested	ARIMA best Fit (pdq)	p-value	Intervention estimate (95% CI)	Comments
Step – CDC guideline	(1,1,2)	0.514	-0.0023 (-0.0091, 0.0045)	Intervention not significant
Step – Canadian prescribing guidelines	(1,0,0)	0.007	-0.0076 (-0.0132, -0.0021)	Intervention is significant; effect estimate indicates lower incidence of potential tapering
Step – SOP guidelines	(1,0,0)	0.002	-0.0084 (-0.0138, -0.0030)	Intervention is significant; effect estimate indicates lower incidence of potential tapering
Step – CPSA's Snapshot Report	(1,0,0)	0.002	-0.0013 (-0.0022, -0.0005)	Intervention is significant; effect estimate indicates lower incidence of potential tapering
Ramp – CDC guideline	(1,0,0)	0.170	-0.0001 (-0.0002, 0.00003)	Intervention not significant
Ramp – Canadian prescribing guidelines	(0,1,1)	0.640	-0.0001 (-0.0006, 0.0004)	Intervention not significant
Ramp – SOP guidelines	(0,1,1)	0.645	-0.0001 (-0.0006, 0.0004)	Intervention not significant
Ramp – 1st CPSA's Snapshot Report	(0,1,1)	0.541	-0.0001 (-0.0006, 0.0003)	Intervention not significant

Table 3

ARIMA models for chronic high dose recipients who experienced discontinuation.

Chronic high dose recipients (discontinuation)				
Intervention tested	ARIMA best Fit (pdq)	p-value	Intervention estimate (95% CI)	Comments
Step – CDC guideline	(1,0,0)	0.007	-0.0023 (-0.0040, -0.0006)	Intervention is significant; effect estimate indicates decreased discontinuation trend
Step – Canadian prescribing guidelines	(3,1,2)	0.892	0.0001 (-0.0020, 0.0023)	Intervention not significant
Step – SOP guidelines	(3,1,2)	0.890	-0.0001 (-0.0023, 0.0020)	Intervention not significant
Step – CPSA's Snapshot Report	(3,1,2)	0.096	-0.0005 (-0.0012, 0.0001)	Intervention not significant
Ramp – CDC guideline	(3,1,2)	0.906	1e-05 (-0.0002, 0.0002)	Intervention not significant
Ramp – Canadian prescribing guidelines	(3,1,2)	0.996	-5e-07 (-0.0002, 0.0002)	Intervention not significant
Ramp – SOP guidelines	(3,1,2)	0.900	1.2e-05 (-0.0002, 0.0002)	Intervention not significant
Ramp – 1st CPSA's Snapshot Report	(3,1,2)	0.988	-1.4e-06 (-0.0002, 0.0002)	Intervention not significant

Table 4

ARIMA models for chronic very high dose recipients who experienced discontinuation.

Chronic very high dose recipients ($\geq 50\%$ dose reduction)				
Intervention tested	ARIMA best Fit (pdq)	p-value	Intervention estimate (95% CI)	Comments
Step – CDC guideline	(1,1,1)	0.254	-0.0015 (-0.0040, 0.0011)	Intervention not significant
Step – Canadian prescribing guidelines	(1,1,1)	0.932	-0.0001 (-0.0027, 0.0025)	Intervention not significant
Step – SOP guidelines	(1,1,1)	0.383	0.0011 (-0.0014, 0.0036)	Intervention not significant
Step – CPSA's Snapshot Report	(3,1,0)	0.734	-0.0002 (-0.0010, 0.0007)	Intervention not significant
Ramp – CDC guideline	(3,1,0)	0.686	0.00004 (-0.0001, 0.0002)	Intervention not significant
Ramp – Canadian prescribing guidelines	(3,1,0)	0.690	0.00004 (-0.0002, 0.0002)	Intervention not significant
Ramp – SOP guidelines	(3,1,0)	0.660	0.00004 (-0.0002, 0.0002)	Intervention not significant
Ramp – 1st CPSA's Snapshot Report	(3,1,0)	0.816	0.00002 (-0.0002, 0.0002)	Intervention not significant